Hadyn has an extensive background in the Life Science sector. During his fifteen-year career at Zeneca/Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the world’s largest seed companies. More recently he was CEO of MNL Pharmaceuticals, a company that was focused on pioneering a novel approach in immunology. Hadyn is also Chairman of Help For Heroes, a charity founded in 2007 to support wounded British soldiers.
Simon has eighteen years of global commercial experience in biotechnology R&D in various roles at Syngenta in the United Kingdom and the United States, leading collaborative programs and delivering biotechnology products in crops for feed and fuel. Additionally, whilst at Syngenta he also worked as the R&D lead on technology acquisition on various agreements. Immediately prior to joining Oxitec, he was Senior Director of Research and Development Programs at Sapphire Energy, a start-up making algae based fuel, based in San Diego, California. Simon has a BSc in biochemistry from UCL and PhD in plant molecular biology from the University of Leicester.
Bill joins us from Bayer Healthcare having held senior finance positions in Europe and the USA. He has a law degree from Cambridge University and is a qualified ACMA. Previously, Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics.
Camilla has extensive international experience in the regulation of biotechnology products and crops. She obtained commercial food approval in the UK for the first GM crop in Europe, and obtained registrations for numerous biotechnology crops in Africa, Asia and the Americas. She advised the Humanitarian Board for Golden Rice on regulatory matters (1997 to 2004), and was a member of both US (BIO) and European Inter-industry groups (EUROPABIO) on The Cartagena Biosafety Protocol, Convention on Biological Diversity and Plant made Pharmaceuticals. Her most recent post was International Regulatory Manager for Syngenta Biotechnology Inc., based in San Diego, California.
Glen has worked in agribusiness since 1998 when he joined Zeneca Agrochemicals as Head of Strategy. There he championed the role of biotechnology in integrated crop solutions, leading to the merger that formed Syngenta. He then worked in independent consulting roles addressing high profile marketing and strategy projects for Syngenta, Arysta and other agribusiness firms. In parallel to this work, Glen set up and ran two IT-related companies. He has a degree from Cambridge University and an MBA from Insead.
The Board of Directors is responsible for Oxitec’s corporate governance and is ultimately accountable for our activities, strategy and financial performance. The Board is comprised of Hadyn Parry CEO, Dr Luke Alphey CSO and the following non-executive directors:
Chris has more than 25 years’ experience in the agriculture and public health fields. In 20 years with ICI, Zeneca and Syngenta, he had very wide experience in technical and commercial areas, including ICI Public Health and general management roles in S America and Asia. In 2003, he was appointed CEO of Arysta LifeScience, the Tokyo-based international agrochemical company and was responsible for transforming the company into a powerful global force in the sector. From 2010, Chris has been Chairman of Arysta LifeScience, and is also Chairman of Plant Health Care plc, a leading provider of naturally derived plant growth enhancers. He is Non-Executive Director of Cibus Global, a bio-technology company and of Dechra Pharmaceuticals plc, an international veterinary pharmaceutical business. Prior to joining the private sector in 1983, he worked in research with the Ministry of Agriculture, Fisheries and Food of the UK. Chris earned a master’s degree in zoology and a D. Phil. in ecology at St. John’s College, Oxford University.
After completing a degree at Cambridge University and a PhD at the University of Dundee, Luke held research posts at Imperial College, London and the University of Dundee, was a lecturer at the University of Manchester and then became an MRC Senior Research Fellow and Reader in Genetics at the Department of Zoology at Oxford University, where he is now a Visiting Professor. Luke is also Group Leader of Vector-borne Viral Diseases at The Pirbright Institute. He is the inventor of the RIDL® system, and a founder of Oxitec.
Landon is a Managing Member of East Hill Advisors, Chairman of the Clay Mathematics Institute, and Chairman of the Caribbean Conservation Corporation. Prior to founding East Hill, he was CEO and Chairman of Eaton Vance. Landon serves on various other boards including the Museum of Fine Arts, Boston. He received an AB cum laude from Harvard College.
Ted founded and is Chairman & Chief Executive of Oxford Capital Partners LLP, an international private equity group. After an early career in the USA with a leading technology group, Corning Inc., Ted pursued a career in international investment banking in New York, Paris, London and Hong Kong. Ted is a graduate of Cambridge University (MA Economics) and INSEAD Business School (MBA), and speaks fluent English, French and German. He is an experienced builder of businesses, investment manager, capital markets specialist, and strategy consultant. He serves on the boards of several companies, public and private, as a non-executive director, in the fields of advanced technologies and life sciences. He has a keen interest in sustainability and governance.
Dr Towler was educated in the life sciences and then spent 23 years in the Pharmaceutical Industry, 13 of which were as leader of a project management organisation. He also led a variety of projects and programmes relating to drug development and organisational change in an international context. In particular, Chris led the teams responsible for the development of Imigran, Zofran and Relenza. Chris joined Imperial College in 2001 to assist new Vice Chancellor, Sir Richard Sykes, particularly in the realms of complex project management, commercialisation of science and communication. He joined Oxford University in 2008 as Director of Oxford Spinout Equity Management to create a new unit with responsibility for management of University’s shareholdings in its spinouts and investment of University funds in portfolio companies. Chris is a non-executive director of a number of life-science based spinouts.
Bryan Morton founded EUSA Pharma, Inc. a transatlantic speciality pharmaceutical company focused on oncology and critical care. Bryan was the President and CEO of EUSA from 2006 until the sale of the company to Jazz Pharmaceuticals for a total consideration of $700m. Prior to EUSA, Bryan was the CEO of Zeneus Pharma, which he founded following the $120m acquisition of Elan’s European business. Zeneus was subsequently acquired by Cephalon in late 2005 for $360m after two highly successful years of rapid growth and profitable trading.
Bryan’s entrepreneurial success is built on 30 years of commercial business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and Bristol Myers Squibb. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at Board and SVP level, in America, the UK, Belgium and Australia.
Bryan is a Non-executive Chairman of Aircraft Medical, Non-executive Chairman of the Aim listed stem cell company ReNeuron, Chairman of Oxford BioTherapeutics, Glide Pharma and VHsquared. Bryan is also a Non-executive Director on the Syncona LLP Board and the Oxitec Board.
Bryan holds an MBA from Durham University, a BSc in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme.
W. Gage McAfee is Managing Director of The Asia Pacific Capital Group, a pan-Asian private equity asset manager. He also holds directorships in a number of Asian-based companies. He served as Chairman of the Main Board Listing Committee and the GEM Listing Committee of The Stock Exchange of Hong Kong Limited and as a member of Dual Listing Advisory Committee of Securities and Futures Commission.
In 1992, Mr. McAfee founded Asia Pacific Capital, the original company of the Asia Pacific Capital Group. He made a series of private equity investments in the entertainment and multimedia area, including multiplex theatres in China, Taiwan, Hong Kong, Malaysia, and Singapore. Mr. McAfee has lived and worked in Hong Kong and Southeast Asia since the late 1960s. He served with the U.S. State Department in Vietnam from 1969 to 1971 and was also an Adjunct Professor at the Saigon Law School. For more than twenty years, he was with the American law firm Coudert Brothers where he was a founder of their East Asia group in Singapore and later the senior partner in Hong Kong. He is also a founding partner of the Hong Kong-based private equity group ChinaVest, widely credited as one of the first venture firms to enter China.
A former chairman of the American Chamber of Commerce in Hong Kong, Mr. McAfee has acted as an adviser to the Asian Development Bank, served on the General Committee of the Hong Kong General Chamber of Commerce, the Law Reform Commission, and was Deputy Chairman of the Hong Kong Community Chest. Mr. McAfee is a member of the Council on Foreign Relations, the Asia Center Committee of Harvard University, served as Board of Governors of the Chinese International School and served as an adviser to the Hong Kong Basic Law Consultative Committee. Mr. McAfee received an A.B. in Government from Harvard University and a J.D. from Columbia University School of Law.